

**NC Medicaid
Outpatient Pharmacy
Prior Approval Criteria
Gocovri and Osmolex ER**

**Medicaid and Health Choice
Effective Date: February 26, 2019
Amended Date: October 14, 2019**

Therapeutic Class Code: H6A

Therapeutic Class Description: Drugs to Treat Movement Disorders

| Medication | Generic Code Number(s) | NDC Number(s) |
|------------|------------------------|---------------|
| Gocovri | 43787, 43788 | |
| Osmolex ER | 44471, 44472, 44473 | |

Eligible Beneficiaries

NC Medicaid (Medicaid) beneficiaries shall be enrolled on the date of service and may have service restrictions due to their eligibility category that would make them ineligible for this service.

NC Health Choice (NCHC) beneficiaries, ages 6 through 18 years of age, shall be enrolled on the date of service to be eligible, and must meet policy coverage criteria, unless otherwise specified. **EPSDT does not apply to NCHC beneficiaries.**

EPSDT Special Provision: Exception to Policy Limitations for Beneficiaries under 21 Years of Age

42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiaries under 21 years of age **if** the service is **medically necessary health care** to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed clinician). This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his/her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems. Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary’s physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary’s right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product, or procedure

- a. that is unsafe, ineffective, or experimental/investigational.
- b. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and/or other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider’s documentation shows that the requested service is medically necessary “to correct or ameliorate a defect, physical or mental illness, or a condition” [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary’s health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

EPSDT and Prior Approval Requirements

EPSDT DOES NOT ELIMINATE THE REQUIREMENT FOR PRIOR APPROVAL IF PRIOR APPROVAL IS REQUIRED. Additional information on EPSDT guidelines may be accessed at <https://medicaid.ncdhhs.gov/medicaid/get-started/find-programs-and-services-right-you/medicaid-benefit-children-and-adolescents>.

Criteria for Initial Coverage of Gocovri:

- Beneficiary has a diagnosis of dyskinesia due to Parkinson's disease and is receiving levodopa-based therapy, with or without dopaminergic medications
- Beneficiary is age 18 or older
- Beneficiary has no contraindications including ESRD (creatinine clearance <15 ml/min/1.73m²)
- Beneficiary has failure, contraindication, or intolerance to immediate-release amantadine (capsule, tablet, or oral solution)
- Initial approval shall be for up to 6 months.

Criteria for Continuation of Coverage of Gocovri:

- All of the above criteria for initial coverage of Gocovri are met.
- Documentation is submitted that indicates the beneficiary has had an improvement in their symptoms from baseline.
- Reauthorization shall be for up to 12 months.

Criteria for Initial Coverage of Osmolex ER:

- Beneficiary has a diagnosis of Parkinson's disease or Drug-induced extrapyramidal reactions
- Beneficiary is age 18 or older
- Beneficiary has no contraindications including ESRD (creatinine clearance <15 ml/min/1.73m²)
- Beneficiary has failure, contraindication, or intolerance to immediate-release amantadine (capsule, tablet, or oral solution)
- Initial approval shall be for up to 6 months.

Criteria for Continuation of Coverage of Osmolex ER:

- All of the above criteria for initial coverage of Osmolex ER are met.
- Documentation is submitted that indicates the beneficiary has had an improvement in their symptoms from baseline.
- Reauthorization shall be for up to 12 months.

**NC Medicaid
Outpatient Pharmacy
Prior Approval Criteria
Gocovri and Osmolex ER**

**Medicaid and Health Choice
Effective Date: February 26, 2019
Amended Date: October 14, 2019**

References

1. Prescriber Information – Gocovri. Adamas Pharmaceuticals, Inc. Emeryville, CA. Revised 08/2017.
2. Prescriber Information- Osmolex ER. Vertical Pharmaceuticals, LLC. Bridgewater, NJ. Revised 07/2018.

**NC Medicaid
Outpatient Pharmacy
Prior Approval Criteria
Gocovri and Osmolex ER**

**Medicaid and Health Choice
Effective Date: February 26, 2019
Amended Date: October 14, 2019**

Criteria Change Log

| 02/26/2018 | Criteria effective date |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10/14/2019 | Added criteria for Osmolex ER. Added for age 18 and over to Gocovri. Clarified on continuation on Gocovri that you must have met the initial criteria for Gocovri in order to have approval for continuation of coverage. Added Osmolex to title |
| | |
| | |
| | |
| | |